Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Carcinogenesis

• Publication date

  2012-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/mc.20795PMID 21557332PMCID PMC3162984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration

  2011cited by this paper
• Microsatellite instability in colorectal cancer

  2011cited by this paper
• A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

  2011cited by this paper
• Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

  2010cited by this paper
• Microsatellite instability in colorectal cancer.

  2010cited by this paper
• Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53

  2010cited by this paper
• TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.

  2010cited by this paper
• DNA damage response to the Mdm2 inhibitor nutlin-3.

  2010cited by this paper
• p53 Mutation Status Predicts Pathological Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer

  2010cited by this paper
• p53 Genotype Predicts Response to Chemotherapy in Patients with Squamous Cell Carcinoma of the Esophagus

  2010cited by this paper
• DNA mismatch repair (MMR)‐dependent 5‐fluorouracil cytotoxicity and the potential for new therapeutic targets

  2009cited by this paper
• TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

  2009cited by this paper
• Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo

  2009cited by this paper
• Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma

  2009influential reference
• CK1α Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability

  2009cited by this paper
• Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5‐fluorouracil in colorectal cancer

  2009cited by this paper
• E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

  2008cited by this paper
• Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

  2008cited by this paper
• Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

  2008cited by this paper
• Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.

  2007cited by this paper
• Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.

  2007cited by this paper
• Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

  2007cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007cited by this paper
• p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene

  2006influential reference
• Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  2006cited by this paper
• Double Bolt Regulation of Rad51 by p53: A Role for Transcriptional Repression

  2006influential reference
• Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

  2006cited by this paper
• Circumvention and reactivation of the p53 oncogene checkpoint in mouse colon tumors.

  2006cited by this paper
• p53 in recombination and repair

  2006cited by this paper
• Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

  2006cited by this paper
• Modeling the therapeutic efficacy of p53 restoration in tumors.

  2006cited by this paper
• MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

  2006cited by this paper
• Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.

  2006cited by this paper
• Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.

  2005cited by this paper
• Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane‐induced colon cancer cell line

  2005cited by this paper
• Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

  2005cited by this paper
• MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

  2005cited by this paper
• Characterisation of the promoter region of the human DNA-repair gene Rad51.

  2005influential reference
• p53's double life: transactivation-independent repression of homologous recombination.

  2004cited by this paper
• Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis*♦

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Targeting the p53–MDM2 interaction to treat cancer

  2004cited by this paper
• Carcinogen-induced colon tumors in mice are chromosomally stable and are characterized by low-level microsatellite instability

  2004cited by this paper
• p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination.

  2003cited by this paper
• DNA Substrate Dependence of p53-Mediated Regulation of Double-Strand Break Repair

  2002cited by this paper
• Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model.

  2002cited by this paper
• The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.

  2001cited by this paper
• Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization.

  2000cited by this paper
• p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53*

  2000cited by this paper
• p76 MDM2 Inhibits the Ability of p90 MDM2 to Destabilize p53*

  2000cited by this paper
• Regulation of p53 stability and activity in response to genotoxic stress.

  2000cited by this paper
• Regulation of p53 in response to DNA damage

  1999cited by this paper
• Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53

  1999cited by this paper
• Mutant p53 proteins stimulate spontaneous and radiation-induced intrachromosomal homologous recombination independently of the alteration of the transactivation activity and of the G1 checkpoint

  1999cited by this paper
• Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.

  1999cited by this paper
• P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.

  1999cited by this paper
• Mechanisms of switching on p53: a role for covalent modification?

  1999cited by this paper
• Accumulated clonal genetic alterations in familial and sporadic colorectal carcinomas with widespread instability in microsatellite sequences.

  1998cited by this paper
• Specific Mismatch Recognition in Heteroduplex Intermediates by p53 Suggests a Role in Fidelity Control of Homologous Recombination

  1998cited by this paper
• The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2

  1998cited by this paper
• Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.

  1998cited by this paper
• Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells.

  1994cited by this paper
• Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.

  1994cited by this paper
• Relationship amongp53, stage, and prognosis of large bowel cancer

  1994cited by this paper
• p53 in colorectal cancer: clinicopathological correlation and prognostic significance.

  1991cited by this paper
• EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.

  1963cited by this paper
• Biochemical changes during treatment with 5-fluorouracil.

  1962cited by this paper

• Exploring the therapeutic role of carnosol in cancer: from molecular insights to clinical promise

  2025cites this paper
• Combining the NanaPPI Toolbox and AI-Driven Virtual Inhibitor Screening for the p53-MDM2 Interaction.

  2025cites this paper
• RBM47 functions as an anti-oncogene by regulating expression and alternative splicing of cell proliferation and apoptosis associated genes in colorectal cancer cells

  2025cites this paper
• MDM2: current research status and prospects of tumor treatment

  2024cites this paper
• 5-Methylcoumarin-4β-glucoside mitigated colon tumor progression in mice with AOM/DSS-induced colon carcinogenesis

  2024cites this paper
• A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma

  2023cites this paper
• Recent Advancements on the Anti-Tumor Small Molecule Inhibitors Targeting the p53-MDM2 Interaction

  2023cites this paper
• Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review

  2023cites this paper
• Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death

  2022cites this paper
• p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition.

  2022cites this paper
• Long-term cultivation using ineffective MDM2 inhibitor concentrations alters the drug sensitivity profiles of PL21 leukaemia cells

  2020cites this paper
• LINC00342 regulates cell proliferation, apoptosis, migration and invasion in colon adenocarcinoma via miR-545-5p/MDM2 axis.

  2020cites this paper
• Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill

  2020influential citation
• Some Important Targets For Development Of Anticancer Drugs

  2020cites this paper
• Roles of DANCR/microRNA-518a-3p/MDMA ceRNA network in the growth and malignant behaviors of colon cancer cells

  2020cites this paper
• Colorectal cancer triple co-culture spheroid model to assess the biocompatibility and anticancer properties of polymeric nanoparticles.

  2020cites this paper
• Forced Overexpression of Translationally Controlled Tumor Protein ( TCTP / TPT 1 ) Induces a Growth-Dysregulated Phenotype in Endothelial and Smooth Muscle Cells : Role of TCTP Exosomal Export in Paracrine Cell-Cell Signaling Induced by Endothelial Injury

  2019cites this paper
• Cytogenetic and Transcriptomic Analysis of Human Endometrial MSC Retaining Proliferative Activity after Sublethal Heat Shock

  2018cites this paper
• Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.

  2017cites this paper
• CMIP Promotes Proliferation and Metastasis in Human Glioma

  2017cites this paper
• Inhibition of the kinase Wee 1-Cytotoxic mechanisms and autoprotection by the tumor suppressor p 53 INAUGURAL –

  2017cites this paper
• ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin

  2016cites this paper
• The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression.

  2016cites this paper
• Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.

  2016cites this paper
• Carnosic acid inhibits STAT3 signaling and induces apoptosis through generation of ROS in human colon cancer HCT116 cells

  2016cites this paper
• Efficient Activation of Apoptotic Signaling during Mitotic Arrest with AK301

  2016cites this paper
• Modulation of p53 signalling and response to MDM2-p53 binding antagonists

  2016cites this paper
• Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors

  2015cites this paper
• P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.

  2015cites this paper
• Accentuating Death Signaling in Colon Cancer Cells: A Chemical Biology Approach

  2015cites this paper
• Human Macrophages B Coregulate Proinflammatory Gene Responses in κ p 53 and NF-Updated

  2014cites this paper
• Extending multi-label feature selection with KEGG pathway information for microarray data analysis

  2014cites this paper
• Microenvironment and Immunology p 53 and NFk B Coregulate Proin fl ammatory Gene Responses in Human Macrophages

  2014cites this paper
• p53 and NF-κB coregulate proinflammatory gene responses in human macrophages.

  2014cites this paper
• Oncogenes and Tumor Suppressor Genes as a Biomarker in Breast Cancer

  2014cites this paper
• Responses in Human Macrophages

  2014cites this paper
• Drugging the p53 pathway: understanding the route to clinical efficacy

  2014cites this paper
• Resistance acquisition to MDM2 inhibitors.

  2014cites this paper
• DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected].

  2014cites this paper
• Carnosol induces apoptosis through generation of ROS and inactivation of STAT3 signaling in human colon cancer HCT116 cells.

  2014cites this paper
• DRAGO ( KIAA0247 ), a New DNA Damage–responsive, p53-inducible Gene that cooperates With p53 as Oncosupprossor

  2014cites this paper
• Novel Piperazine-based Compounds Inhibit Microtubule Dynamics and Sensitize Colon Cancer Cells to Tumor Necrosis Factor-induced Apoptosis*

  2013cites this paper
• Role of α5β1 integrin/p53 pathway in the resistance of glioma and colon cancer to therapy

  2013cites this paper
• Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53‐independent pancreatic cancer cell death

  2013cites this paper
• Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells.

  2013cites this paper
• Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligands

  2013cites this paper
• AD-1, a novel ginsenoside derivative, shows anti-lung cancer activity via activation of p38 MAPK pathway and generation of reactive oxygen species.

  2013cites this paper
• Targeting the p 53 – MDM 2 interaction by the small-molecule MDM 2 antagonist Nutlin-3 a : a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients

  2013cites this paper
• Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.

  2012cites this paper
• Hyperbaric oxygen preconditioning protects skin from UV-A damage

  2012cites this paper
• The Important Molecular Markers on Chromosome 17 and Their Clinical Impact in Breast Cancer

  2011cites this paper